ArticleFrontiers in immunology2025
Yang-deficiency constitution drives poor outcomes in clear cell renal cell carcinoma by modulating the tumour immune microenvironment.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, often diagnosed at advanced stages due to a lack of reliable early biomarkers. Recent studies suggest that the traditional Chinese medicine (TCM) body constitution, particularly the Yang-Deficiency Constitution (YDC), may influence tumour development by altering the immune microenvironment. However, the mechanistic connection between YDC and ccRCC prognosis remains largely unexplored. Objective: This study aims to elucidate the impact of YDC on the immune landscape and clinical outcomes of ccRCC and to identify novel prognostic biomarkers and potential herbal therapeutic agents guided by YDC characteristics. Methods: We integrated bulk transcriptomic data from 12 YDC-classified individuals and 530 ccRCC patients, alongside single-cell RNA-seq profiles from one PBMC and two ccRCC tumour samples. Through differential expression analysis, WGCNA, and machine learning-based survival modelling, we identified YDC-related biomarkers and assessed their immunological relevance using ESTIMATE, CIBERSORT, and CellChat. A gene expression-based scoring framework (GSVA) was developed to systematically prioritize 622 herbal ingredient perturbations for their potential survival benefits. Key ingredients were further validated through molecular docking and experimental assays. Results: Patients with YDC-associated ccRCC exhibited poorer survival. Nine intersecting genes were screened and used to construct a prognostic model, whereby seven key biomarkers-MXD3, PLCB2, CCDC88B, DEF6, IFNG, TBC1D10C, and PLEKHN1-were significantly influenced the prognosis of renal cancer. These genes were found to modulate immune cell populations, particularly CD8 Conclusion: This study highlights the crucial role of YDC in shaping the immune microenvironment and influencing survival in ccRCC. By integrating constitution-based stratification, immune profiling, and herbal medicine screening, we offer a unique framework for biomarker discovery and propose baicalein as a potential YDC-targeted adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.